Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
schizophrenia drug
Biotech
Karuna's schizophrenia drug clears blood pressure test
Karuna posted phase 1b data that counter concerns about the effect of its blockbuster-in-waiting schizophrenia therapy on blood pressure.
Nick Paul Taylor
Nov 17, 2023 8:52am
Newron's schizophrenia data boost chances of historic approval
Feb 16, 2023 8:30am
Karuna hits goal in schizophrenia phase 3, teeing up 2023 filing
Aug 8, 2022 9:48am
Cerevel stock doubles on success of phase 1b schizophrenia trial
Jun 30, 2021 7:15am
Alkermes sees swift turnaround for rejected schizophrenia med
Dec 29, 2020 8:18am
Newron delays pivotal schizophrenia trials amid safety fears
May 28, 2019 7:22am